Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
53
NDRA Quote, Financials, Valuation and Earnings
Last price:
$7.40
Seasonality move
:
-20.79%
Day range:
$7.01 - $7.45
52-week range:
$2.90 - $168.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.82x
P/B ratio:
3.14x
Volume:
92.1K
Avg. volume:
3.3M
1-year change:
-95.21%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$483.49
Analysts' Opinion
-
Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.00, ENDRA Life Sciences has an estimated upside of 517.45% from its current price of $7.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $46.00 representing 100% downside risk from its current price of $7.45.
Fair Value
-
According to the consensus of 1 analyst, ENDRA Life Sciences has 517.45% upside to fair value with a price target of $46.00 per share.
NDRA vs. S&P 500
-
Over the past 5 trading days, ENDRA Life Sciences has underperformed the S&P 500 by -7.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ENDRA Life Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ENDRA Life Sciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ENDRA Life Sciences reported revenues of --.
Earnings Growth
-
ENDRA Life Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ENDRA Life Sciences reported earnings per share of -$1.86.
Enterprise value:
3.4M
EV / Invested capital:
--
Price / LTM sales:
5.82x
EV / EBIT:
--
EV / Revenue:
9.60x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$13.2M | -$10.4M | -$9.5M | -$2.8M | -$1.5M | |
| EBITDA | -$13M | -$10.1M | -$9.3M | -$2.7M | -$1.4M | |
| Diluted EPS | -$7,385.00 | -$2,093.12 | -$483.49 | -$449.58 | -$1.86 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.4M | $10.1M | $5.5M | $1.3M | $2.2M | |
| Total Assets | $18.9M | $10.9M | $6.7M | $5.1M | $3.2M | |
| Current Liabilities | $765.8K | $1.4M | $1.8M | $1.2M | $565.8K | |
| Total Liabilities | $1M | $1.9M | $2.2M | $1.4M | $1.4M | |
| Total Equity | $17.9M | $9.1M | $4.5M | $3.7M | $1.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.2M | -$9.2M | -$6.5M | -$2.1M | -$1.3M | |
| Cash From Investing | -$140.2K | -$21.5K | -$6.3K | -$23.8K | -$17.3K | |
| Cash From Financing | $7.5M | $8M | $7.5M | $468.9K | $145.8K | |
| Free Cash Flow | -$12.3M | -$9.2M | -$6.6M | -$2.2M | -$1.3M | |
NDRA
Sector
Market Cap
$5.5M
$35.2M
Price % of 52-Week High
4.43%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-95.21%
-36.85%
Beta (5-Year)
-0.178
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.01
200-day SMA
Buy
Level
$5.24
Bollinger Bands (100)
Buy
Level
2.84 - 5.62
Chaikin Money Flow
Sell
Level
-42.2M
20-day SMA
Buy
Level
$5.26
Relative Strength Index (RSI14)
Buy
Level
67.95
ADX Line
Buy
Level
36.71
Williams %R
Neutral
Level
-51.8987
50-day SMA
Buy
Level
$4.26
MACD (12, 26)
Buy
Level
2.15
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
92.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Stock Forecast FAQ
In the current month, NDRA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NDRA average analyst price target in the past 3 months is $46.00.
-
Where Will ENDRA Life Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that ENDRA Life Sciences share price will rise to $46.00 per share over the next 12 months.
-
What Do Analysts Say About ENDRA Life Sciences?
Analysts are divided on their view about ENDRA Life Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ENDRA Life Sciences is a Sell and believe this share price will drop from its current level to $46.00.
-
What Is ENDRA Life Sciences's Price Target?
The price target for ENDRA Life Sciences over the next 1-year time period is forecast to be $46.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NDRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ENDRA Life Sciences is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of NDRA?
You can purchase shares of ENDRA Life Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ENDRA Life Sciences shares.
-
What Is The ENDRA Life Sciences Share Price Today?
ENDRA Life Sciences was last trading at $7.40 per share. This represents the most recent stock quote for ENDRA Life Sciences. Yesterday, ENDRA Life Sciences closed at $7.45 per share.
-
How To Buy ENDRA Life Sciences Stock Online?
In order to purchase ENDRA Life Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
